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The Centers for Medicare & Medicaid Services (CMS) recently issued a national coverage 
determination (NCD) on next generation tumor sequencing tests (NGTS) for patients with 
advanced cancer (see Box for definitions). The CMS policy provides coverage for NGTS 
tests that received a positive FDA review and that have FDA approved indications for 
patients with advanced solid cancers. NGTS tests must serve as companion diagnostics to 
target specific drug treatment(s). Labs that choose not to seek FDA review for their NGTS 
tests can seek local coverage determinations through CMS Medicare Administrative 
Contractors (MACs). Both the draft issuance on November 30, 2017 and the final policy 
issued on March 16, 2018 generated a great deal of controversy; over 300 comments were 
submitted to CMS during the public comment period on the draft issuance and numerous 
commentaries and news items have been published.
In this commentary, we argue that the new CMS policy (1) presents a key shift in coverage 
criteria for NGTS, and (2) has important implications beyond Medicare for private payer and 
Medicaid coverage policies. Our commentary draws on our prior and ongoing studies of 
coverage policies.(1–3) We also use insights from a meeting held on March 9, 2018, and 
accompanying survey conducted with our UCSF Center for Translational and Policy 
Research on Personalized Medicine (TRANSPERS) Payer Advisory Board. The Board 
includes senior executives from the largest private health plans, a Medicaid plan and leading 
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regional private plans, as well as other thought leaders with expertise in coverage and 
reimbursement by Medicare and other payers.(4) We also build on our prior work that 
examined the broader health policy implications of the new CMS policy.(5, 6) Although 
observers have commented on the importance of the policy for private payers, there has been 
no assessment of the policy’s implications for these payers and for Medicaid plans. Our 
previous work showed limited coverage of NGTS by private payers(7) and our more recent 
analyses of the largest private payers (unpublished data) confirmed that coverage of NGTS 
specifically is variable. Some payers cover NGTS only for specific cancer sites (e.g., non-
small cell lung cancer) and others cover only panels with a limited number of genes (e.g., 
less than 50). For state Medicaid plans, we are unaware of any published analyses of NGTS 
coverage policies, but coverage has been described as limited and variable.(8)
(1) Why the CMS Policy Represents a Key Shift in Coverage Criteria
The new CMS policy represents a departure from Medicare’s previous criteria as well as 
from criteria currently used for NGTS coverage by private payers and Medicaid plans in 
several ways (Table 1).
Notably, there are criteria that some private payers use that were not included in the CMS 
policy, e.g., that sequential single-gene testing is found to be impractical for a patient before 
they will cover a panel. As another example, some private payer policies refer to guidelines 
such as those by the National Comprehensive Cancer Network (NCCN) and this criterion 
was not mentioned in the CMS policy.
One feature of the CMS policy included in the draft but not in the final version would have 
represented another key shift in the criteria used: the proposed pathway for tests not meeting 
the coverage criteria to still be covered via Medicare’s “coverage with evidence 
development” program if laboratories collected the required data. This approach had been 
recommended by some observers(9) but generated intense debate. Our discussions with 
private and Medicaid payers suggest that they perceived that the adoption and 
implementation of CED would be very difficult.
(2) Implications for Private Payers and Medicaid Plans
We argue that there are three key implications for private payers and Medicaid plans:
1. Private payers and Medicaid plans will carefully review the CMS policy and monitor its 
implementation, but they may not change their own coverage policies to match those of 
CMS in the short-term.
Our previous research and recent payer input show that CMS policy is a factor in their 
considerations, e.g., in our meeting, payers noted they perceive this policy as important. 
However, contrary to a common assumption, private payers and Medicaid do not always 
follow Medicare policies as Medicare decisions are only one of many factors that they 
consider. For example, a review of 47 Medicare NCDs for medical devices found that 
Medicare policies were equivalent to the corresponding private payer policies only about 
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half the time.(10) Medicaid policies are different for each state and thus can be even more 
variable.
In our discussions with payers, we found that many of them are unsure of their plans or do 
not plan to change their policies to match the CMS policy at least in the short term. Payers 
stated that the new CMS policy provides some benefits and a step forward but they also 
perceived that it creates concerns that have to be addressed because of the significant shift in 
the criteria used as described above. They planned to make their own assessments for 
coverage; as one payer noted, to the extent that conclusions drawn by CMS are well 
supported by analysis of literature and other factors, they would draw the same conclusion 
without the CMS policy.
2. Private payers and Medicaid plans that decide to change their coverage policies to 
match those of CMS will need to make adaptations.
One key difference in the situation faced by private payers versus the CMS is that private 
payers do not have the option of the second coverage pathway that is included in the CMS 
policy – the use of Medicare Administrative Contractors to make local coverage decisions 
for tests not already covered by the national policy. The Medicare program thus has the 
flexibility to adapt policies to local situations, whereas private payers typically do not have 
the flexibility to have differing policies at the national and local levels. Thus, for example, 
even though an FDA positive review is required by the Medicare national coverage policy 
the Medicare local policies may not require this level of review, while private payers will 
have to either require FDA positive review or not require it.
Changes in coverage policies are also likely to have ripple effects on the laboratory and 
medical center industries that will require adaptation by private payers and Medicaid plans. 
Many NGTS tests are developed and conducted at specific laboratories for use at their own 
facilities, such as medical center-based tests. These tests are often not submitted to the FDA 
for approval, unlike the tests developed by large, commercial laboratories. It is possible that 
the CMS national coverage policy requirement for a positive FDA review will encourage 
smaller laboratories to submit their tests for approval and thus increase the number of 
approved tests. However, FDA review can be time-consuming and expensive and thus we 
believe that most smaller laboratories will not pursue this option. The result may be that 
private payers and Medicaid plans have fewer testing options for their patients.
The criteria used in the CMS policy will also require refining definitions such how 
“advanced cancer” is measured, e.g., by incorporating the evolving concept of tumor 
mutational burden (TMB) in solid tumors. Of particular importance will be whether there are 
billing codes (i.e., CPT codes) that capture the needed information and that are consistently 
adopted and implemented. Payers need to be able to track what tests are being ordered and 
reimbursed in order to support their policies. However, we recently found that there remain 
large gaps in the codes used for multigene tests as a category and wide variation in whether 
and how they are implemented.(11)
We also found that some payers are considering or implementing other approaches to deal 
with coverage issues for NGTS that differ from the approach used by CMS. For example, 
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some payers are providing broader coverage but doing so while also implementing 
utilization management programs (e.g., pre-authorization requirements, contracting 
agreements, and/or use of lab benefit managers). Each payer has a different enrollee 
population and faces different financial and logistical situations such that one approach may 
not work for all payers.
3. In the medium to long-term, we expect to see an evolution of coverage such that at 
least some private payers and Medicaid plans will establish positive coverage policies for 
NGTS in at least some clinical situations
By viewing the past development of NGTS policies, we see that they have evolved over time 
and the CMS policy emerged from the gaps in that evolution.(3) A number of experts have 
called for adaptation of coverage frameworks for next-generation sequencing tests(1, 2, 12) 
and several frameworks have been proposed.(12–14) These approaches all have pros and 
cons, and their acceptance and implementation have varied.(3) Regardless, it is clear that the 
lack of positive coverage policies for NGTS (where payers agree to pay for the test provided 
criteria are met) for NGTS was a gap and CMS determined that they needed to address that 
gap.
We can speculate that private payer coverage will evolve over time with at least some 
policies that provide broad coverage for NGTS. Private plans servicing Medicare Advantage 
plans have a mandate to cover NGTS for those enrollees – a dichotomy in their own policy 
that may move them toward consistent coverage for all enrollees. Also, the CMS policy will 
likely increase demand for NGTS by providers and patients that will create greater impetus 
for payers to cover it. In contrast, there is more uncertainty about what Medicaid plans will 
cover given the current political environment and financial pressures.
In sum, the CMS policy represents a key shift in NGTS coverage criteria with implications 
far beyond this specific policy. It will be important to track and assess how other payers 
respond and the impact of policies on patients and providers. We suggest that mechanisms 
be developed so that all relevant stakeholders can participate in an assessment of the 
implementation and implications of this new policy including the benefits and the risks.
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Glossary
National Coverage Determination (NCD)
Nationwide determination of whether Medicare will pay for an item or service. In the 
absence of an NCD, a service is covered at the discretion of regional Medicare 
Administrative Contractors who may issue a Local Coverage Determination (LCD)
Medicare Administrative Contractors (MACs)
A private health care insurer that has been awarded a geographic jurisdiction to process 
Medicare claims
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Next generation tumor sequencing (NGTS
The use of massively parallel technologies to simultaneously examine large numbers of 
genetic tumor alterations
Companion diagnostics
A test that uses genetic information to inform a decision to use a specific drug treatment
FDA positive review
Tests can receive a positive review from the FDA via the “approval” process or if they are 
“cleared” through a determination that they are substantially equivalent to a test already 
approved
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Table 1:
Criteria Used In CMS NCD and How They Represent Key Shifts Compared To Previous CMS and Current 
Private Payer / Medicaid Criteria
Coverage Criteria Used in CMS NCD How CMS NCD Criteria Differs from
Current Criteria Used by Private Payers
and Medicaid Plans
FDA positive review required for test Typically, not required
Test must be a companion diagnostic Typically, not required
No limit on the number of included genes in an NGTS panel Many previous coverage policies and coverage frameworks called for 
limiting coverage of NGTS tests based on a specific number of genes, e.g., a 
proposal by the Center for Medical Technology Green-Park Collaborative 
used 50 genes as a cut-off.(8)
Inclusion of less-studied genes does not define the entire test 
as experimental/investigational and thus not covered
If any included gene was experimental/investigational, this typically made the 
test not coverable.
NGTS tests meeting other policy criteria are covered for any 
advanced solid tumors
Typically, cancer-specific, e.g. non-small cell lung cancer.
Policy focuses on a test method (sequencing) versus the 
testing clinical scenario irrespective of what method is being 
used
Policies more commonly focus on the clinical scenario rather than the test 
method.
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